Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases.
Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases.
复制标题
Sr-89 氯化物与唑来膦酸同时使用对于骨转移疼痛的乳腺癌患者是安全有效的。
DOI：
10.3892/etm.2011.405
复制
发表时间：
2012
影响因子：
2.7
通讯作者：
N. Kohno
中科院分区：
文献类型：
--
作者：
Kimito Yamada;M. Yoshimura;H. Kaise;A. Ogata;N. Ueda;K. Tokuuye;N. Kohno
本研究旨在探讨放射性药物氯化锶(锶-)联合唑来膦酸标准抗癌治疗乳腺癌多灶骨转移疼痛患者的安全性和有效性。这项研究包括16名乳腺癌患者，他们通过核素扫描、计算机断层扫描或磁共振成像发现了疼痛的多灶性骨转移。所有患者在2007年3月至2011年2月期间同时接受SR-89和唑来膦酸治疗，作为包括化疗、内分泌治疗、分子靶向治疗和靶向放射治疗的标准治疗方案的一部分。SR-89按2MBq/kg静脉注射，每人最多141MBq。安全性根据《不良事件通用术语标准》(v3.0)衡量的骨髓毒性进行评估。为了评估治疗效果，我们监测了止痛药剂量的变化。此外，我们还利用锶-给药后的韧致辐射成像研究了锶-在转移部位的蓄积与疗效的关系。根据结果，16名患者中共有14名(88%)报告骨痛缓解，表明锶-89与唑来膦酸联用具有很高的疗效。在有反应的病例中，在~(99m)Tc骨显像所示的相同部位，在韧致辐射成像上观察到强摄取锶-89。此外，未观察到严重的骨髓抑制(3级)，不良反应可耐受。综上所述，锶-89与唑来膦酸联合应用于乳腺癌骨转移疼痛患者，与其他标准治疗方案同时使用是安全有效的。今后应考虑早期应用锶-89治疗，并进行大规模临床研究。
Our aim in this study was to examine the safety and efficacy of the concurrent use of the radiopharmaceutical strontium-89 (Sr-89) chloride with zoledronic acid in standard anticancer therapy for breast cancer patients with painful multifocal bone metastases. The study comprised 16 breast cancer patients with painful multifocal bone metastases detected by bone scintigraphy, computed tomography or magnetic resonance imaging. All patients were treated with Sr-89 and zoledronic acid concurrently between March 2007 and February 2011 as part of a standard therapeutic regimen comprising chemotherapy, endocrine therapy, molecular targeting therapy and targeted radiotherapy. Sr-89 was administered intravenously at 2 MBq/kg to a maximum of 141 MBq per person. Safety was evaluated according to myelotoxicity as measured by the Common Terminology Criteria for Adverse Events (v3.0). To assess treatment efficacy, we monitored changes in analgesic drug dosages. Furthermore, bremsstrahlung imaging after the administration of Sr-89 was utilized to examine the relationship between the accumulation of Sr-89 in metastatic sites and treatment efficacy. Based on the results, a total of 14 out of 16 patients (88%) reported bone pain relief, indicating a high efficacy of Sr-89 combined with zoledronic acid. In responsive cases, a strong uptake of Sr-89 was observed on bremsstrahlung imaging at the same sites indicated by (99m)Tc bone scintigraphy. Moreover, severe myelosuppression (> grade 3) was not observed, and adverse events were tolerable. In conclusion, the use of Sr-89 with zoledronic acid in breast cancer patients with painful bone metastases was safe and effective when administered concurrently with other standard therapies. In the future, the treatment with Sr-89 at the early stage should be considered, and a large-scale clinical study should be conducted.